Workflow
康泰生物实控人前妻拟减持 2020定增募30亿跌破增发价

Core Viewpoint - Yuan Liping, a major shareholder of Kangtai Biological, plans to reduce her stake in the company due to personal financial needs, intending to sell up to 11,160,000 shares, which represents 1.00% of the total share capital [1] Group 1: Shareholder Information - Yuan Liping is the second-largest shareholder of Kangtai Biological, holding 201,730,680 shares directly, which is 18.06% of the total share capital, and an additional 45,200,000 shares indirectly, totaling 246,930,680 shares or 22.11% of the total [2] - The actual controller of Kangtai Biological is Du Weimin, and Yuan Liping is considered a concerted actor with him [2] Group 2: Historical Context - In May 2020, Kangtai Biological announced the divorce between Du Weimin and Yuan Liping [3] - The company conducted a non-public offering in 2020, raising a total of RMB 300 million, with a net amount of RMB 298.53 million after expenses, at an issue price of RMB 110 per share [3] - Kangtai Biological's current stock price is below the issue price from the 2020 non-public offering [3] - The company announced a dividend plan in May 2022, proposing a bonus issue of 6 shares for every 10 shares held and a cash dividend of 8.5 yuan (pre-tax) [3]